Dublin-listed pharmaceutical services company Open Orphan has announced that its subsidiary, Hvivo, has developed a controlled human malaria infection challenge model.
In virus challenge studies, healthy volunteers are administered a pathogenic or virulent strain of virus. These challenge agents are then used in controlled human infection studies, an area that Hvivo has focused on since 2001.
The company said the move would both strengthen and further diversify its portfolio of viral challenge study models.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).